FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Ocrelizumab May Improve Cognitive Function in Relapsing MS




















Cognitive impairment is often reported among patients with MS.



Compared with interferon beta-1a, treatment of relapsing forms of MS with ocrelizumab resulted in improved cognitive performance, according to results from a pooled analysis of the phase 3 OPERA studies (ClinicalTrials.gov: NCT01247324, NCT01412333).

The results were presented at the 2017 Consortium of Multiple Sclerosis Centers Annual Meeting, May 24-27 in New Orleans. 

Previous reports have established ocrelizumab's superiority over interferon beta-1a in reducing MS relapses, disability and disease progression, and lesion load and brain atrophy in patients with relapsing MS. The current study sought to evaluate the effect of treatment with ocrelizumab on measurements of cognitive function, including the Paced Auditory Serial Addition Test (PASAT) and the Symbol Digit Modalities Test (SDMT), which measure processing speed and working memory.

The PASAT and SDMT assessments were performed at baseline and every 12 weeks thereafter. In the pooled population, mean (SE) baseline PASAT and SDMT scores were 42.58 (0.460) and 47.34 (0.641) in patients receiving ocrelizumab vs 41.70 (0.477) and 47.31 (0.639) in patient treated with interferon beta-1a, respectively. A modest correlation was observed between SDMT and PASAT scores (0.36; P <.0001).

At 96 weeks, improvement in mean PASAT scores in patients receiving ocrelizumab were greater than in those receiving interferon beta-1a (6.520; SE 0.35, 95% CI, 5.84-7.20 vs 5.651; SE 0.36, 95% CI, 4.95-6.35; P =.0531). Similar improvements were observed in SDMT scores in patients receiving ocrelizumab vs interferon beta-1a (96 weeks: 5.430; SE 0.52, 95% CI, 4.41-6.46 vs 4.046; SE 0.54, 95% CI, 3.00-5.10; P =.0422).


Overall, treatment with ocrelizumab improves cognitive performance in measures of processing speed and working memory better than interferon beta-1a.

Story Source: The above story is based on materials provided by NEUROLOGYADVISOR
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News